Spotlight On... Biogen partners with aim of making its infusion-based meds deliverable via a simple injection; and more...

Biogen ($BIIB) will deploy Arisa Therapeutics' drug delivery technology in a bid to develop subcutaneous injectable formulations of its hemophilia meds. Delivery via an autoinjector instead of an inconvenient infusion machine would make the franchise stand out in the face of current or future competition from Baxalta ($BXLT), Bayer and Novo Nordisk ($NVO). Co-founded by MIT's Robert Langer, Arisa has developed protein formulation technology that decreases the viscosity of biologics without decreasing their potency. The Cambridge, MA, company stands to earn as much as $100 million from the alliance. Demand is high for transitioning infusion drugs to simple injection-based therapies. Halozyme ($HALO) believes its drug delivery technology can pull off the trick too and just added Eli Lilly ($LLY) to its lengthy list of Big Pharma partners. More

> Mallinckrodt ($MNK) expanded its drug delivery offerings with the purchase of three topical hemostasis drugs from The Medicines Company. CEO Mark Trudeau said the new additions will complement the company's injectable med Ofirmev. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.